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PURPOSE. To investigate the predominant mutation in the
CYP1B1 gene in patients in India with primary congenital
glaucoma (PCG), using PCR-restriction fragment length poly-
morphism (RFLP) methods and to characterize the molecular
defect in two generations of an affected family.
METHODS. DNA samples from 146 patients with PCG from 138
pedigrees were analyzed for several distinct mutations in
CYP1B1 by PCR-RFLP.
RESULTS. PCR-RFLP screening revealed that 30.8% of patients
were positive for any one of the six mutations (376insA,
528G3A, 923C3T, 959G3A, 1449G3A, and 1514C3A),
and 17.8% of the patients were found to have the rarely re-
ported mutation R368H (1449G3A). All mutations were con-
firmed by DNA sequencing.
CONCLUSIONS. The results suggest extensive allelic heterogene-
ity in the Indian patients with PCG, with the predominant
allele being R368H among the 146 Indian patients tested. It
appears possible to use this approach for carrier detection in
pedigrees with a positive family history and in population
screening. The approach also offers a method for rapid screen-
ing of potential carriers and affected individuals. (Invest Oph-
thalmol Vis Sci. 2003;44:4200–4203) DOI:10.1167/iovs.02-0945
Primary congenital glaucoma (PCG) manifests at birth or inearly infancy. The phenotype is characterized by elevated
intraocular pressure, resulting in photophobia, corneal cloud-
ing, and enlargement of the globe, which, if left untreated,
results in optic nerve damage and subsequent permanent loss
of vision. The incidence of PCG varies geographically. Its
incidence is as low as 1 in 10,000 persons in Western coun-
tries,1 and as high as 1 in 1,250 in the Slovak population.2 In
Saudi Arabia, the reported incidence is 1 in 2,500,3 whereas in
the state of Andhra Pradesh in India, the incidence is estimated
to be 1 in 3,300.4 The high incidence in the Eastern popula-
tions is thought to be due to consanguineous marriage within
these communities. Because PCG is mainly a congenital disor-
der, early and reliable diagnosis of the disease is vital, so that
appropriate and prompt medical and surgical interventions can
be initiated in time. This could in turn prevent unwanted visual
loss, hence saving the vision in the child.
An autosomal recessive mode of inheritance pattern is well
documented for PCG. Even though three different loci have
been mapped for PCG5,6 (Stoilov IR, et al. IOVS 2002;43:ARVO
E-Abstract 3015), mutations in the CYP1B1 gene (GLC3A lo-
cus5) is the most predominant7 and is reported in various
ethnic backgrounds.7–20 An additional PCG locus, GLC3B,6 has
been mapped to the short arm of chromosome 1, region 36,
and a third locus, GLC3C (Stoilov IR, et al. IOVS 2002;43:ARVO
E-Abstract 3015), to 14q24.3, but the genes have not been
identified in these two loci. Recently, we showed the associa-
tion of CYP1B1 with PCG in the Indian population18 and
detected five distinct mutations.
Although genetic heterogeneity has been shown for PCG,
homogeneity in phenotype as well as genotype (E387K) has
been reported in the Slovakian Romany people, and common
haplotypes (G61E, D374N, R469W) have been associated with
the Saudi Arabian population.11,12 Inbreeding and consanguin-
ity are prevalent in these communities, as in India. Thus, it is of
interest to determine which haplotypes are present in the
Indian patients. Against this background, we now describe the
results of screening for the known mutations in a cohort of 138
pedigrees of 146 patients, by using PCR-RFLP–based simple
diagnostic methods.
MATERIALS AND METHODS
Selection and Evaluation of Study Subjects
The study protocol adhered to the tenets of the Declaration of Helsinki.
After receiving due informed consent and appropriate clearance from
the institutional review board, we recruited 146 patients for the study
who were members of 138 pedigrees. The patients were completely
unbiased with respect to sex, consanguinity, and familial incidence of
the disease. All were clinically evaluated, and diagnosis of PCG was
determined by examination with slit lamp biomicroscopy and gonios-
copy, measurement of intraocular pressure, and perimetry, in some
cases. Blood samples were collected over a period of 2 years in the
Children’s Eye Care Centre at the Institute. Seventy ethnically matched
normal individuals served as control subjects.
Mutation Screening of CYP1B1
Genomic DNA was extracted from the peripheral leukocytes of all
patients with PCG and control subjects. The translated region (1.6 kb)
spanning exons II and III of the gene for cytochrome P4501B1
(CYP1B1)21 from patients and control subjects were amplified by
using three sets of primers, as described earlier.18
PCR-Restriction Fragment Length Polymorphism
and Direct Sequencing
The PCR-RFLP methods described earlier18 were followed, along with
an Hin6I (MBI Fermentas, Vilnius, Lithuania) restriction enzyme–based
RFLP for 1514C3T (R390C) mutation. DNA samples from 70 volun-
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tary donors, without a history of systemic and eye disorders, were used
in control experiments. PCR-RFLP–positive samples were sequenced
(for reconfirming the respective mutations) using an automated DNA
sequencer (Big Dye Terminator cycle sequencing, ABI Prism 3700;
Applied Biosystems, Foster City, CA).
RESULTS
Identification of a Novel Pathogenic Mutation
Direct sequencing of the complete coding region of a pro-
band’s DNA from two generations of an affected pseudodomi-
nant family (005) revealed a compound heterozygous missense
mutation. The first one was a known mutation,12,18,20 a G3A
substitution at base pair position 1449, leading to the amino
acid (aa) change arginine to histidine at position 368 (R368H),
whereas the second mutation was a novel sequence variation,
a C3T substitution at base pair 1514 (Fig. 1A), causing the
change arginine to cysteine at position 390 (R390C). The father
(Fig. 1B, II.1) in the same family, also affected by PCG, was
homozygous for the novel mutation 1514C3T. The grandpar-
ents (I.1 and I.2) as well as the unaffected sibling (III.1) were
heterozygous (carriers) for the mutation. Both mutations,
R368H and R390C were found in exon III and resulted in loss
of restriction sites TaaI and Hin6I respectively. The cosegre-
gation of mutations in the family was ascertained by using the
PCR-RFLP method. In this pedigree, the grandparents (I.1 and
I.2) had a consanguineous marriage, whereas the parents (II.1
and II.2) were nonconsanguineous (Fig. IB).
PCR-RFLP Analyses of Six Pathogenic Mutations
PCR-RFLP analyses were performed for all six mutations:
376insA, 528G3A, 923C3T, 959G3A, 1449G3A, and
1514C3T. Of the 146 patients in 138 pedigrees, 45 patients in
37 pedigrees were positive for one of these six mutations. All
the PCR-RFLP–positive samples were subsequently sequenced
to confirm the mutation. More than 30% of the patients were
carriers of the respective mutation, as revealed later by se-
quencing. Among the six mutations, R368H was the predomi-
nant PCG allele in this cohort, and 17.8% of the patients were
found to be either homozygous or heterozygous for this mu-
tation.
DISCUSSION
PCG is a clinically and genetically heterogeneous disorder,
mainly inherited as an autosomal recessive disease, that occurs
among various populations of the same ethnic background.
Recent molecular genetic studies in various ethnic groups,
such as Turkish, Hispanic, Saudi Arabian, Romanian, Brazilian,
Canadian, Japanese, Pakistani, German, Lebanese, and Indian,
revealed several mutations in the coding region of CYP1B1. All
these studies have so far reported approximately 44 different
mutations in the entire coding region of CYP1B1,17–20 and the
mutations’ heterogeneity varies with the population.
The homogeneity–heterogeneity pattern varies with ethnic
groups, as does the phenotypic uniformity of the condition.
Whereas the Slovak Romany cases showed allelic homogeneity
and phenotypic uniformity,11 other population studies re-
ported high clinical and allelic heterogeneity. Among these
groups, higher homogeneity was present in the Saudi Arabian
population (with 72% having the G61E allele and 12% the
R469W allele12), whereas other populations demonstrated in-
creased genetic heterogeneity. The homogeneity reflects the
higher rate of inbreeding in this population. Our PCR-RFLP
FIGURE 1. (A) Electropherogram of the sense strand of genomic DNA from PCG proband, with novel heterozygous missense mutation. Note the
heterozygous change 1514C3T (R390C) in the mutant allele of the proband (arrow). (B) PCR-RFLP analysis of cosegregation of a mutant allele
with a disease phenotype in a PCG pedigree. Filled square: affected individuals; filled circle: unaffected individuals; arrow: the proband. Males and
females are shown by squares and circles, respectively. Left: DNA molecular weight marker in base pairs; right: allele sizes; lane C: control;
arrowhead: mutant allele. Restriction site change and mutation (nucleotide as well as aa changes) are shown at the bottom of the gel. The 885-bp
amplification product generated from primer pair 3F/3R[19] was cleaved by Hin6I into two fragments of sizes 620 and 265 bp in unaffected
individuals. The C1514T mutation in the affected individuals abolished the Hin 6I site, and the resultant uncut 885-bp mutant allele segregated
along with the disease phenotype. The “normal” Hin6I cleavage products present in affected individuals were generated from the nonmutated
CYP1B1 allele in these individuals.
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screening, for six distinct alleles, in a cohort of 146 patients in
138 pedigrees showed a frequency of 16.21% for allele R368H.
This mutation has so far been reported in only a very few
PCG families from Saudi Arabia and Brazil and at a very low
frequency.12,20 In the present study, however, based on the
mutation screening, we found it to be a predominant allele
associated with PCG in India. This is the highest reported
frequency of this mutation of all ethnic backgrounds studied so
far, indicating that the frequency of the mutation could vary
based on the ethnic origin as well as geographical location.
Sequence analysis of the remaining families negative for these
six mutations should to be performed to determine whether
there are any other predominant alleles in Indian patients with
PCG. The possibility of locus heterogeneity in Indian patients
with PCG also should be explored further.
Ethnically matched population screening of 140 chromo-
somes for these six mutant alleles showed 6.4% and 0.7%
carriers for E229K and R368H, respectively. The present data
are unlikely to be due to a possible founder effect for the
predominant R368H allele, because patients were from ethni-
cally as well as geographically diverse groups in India. Also,
these mutations are equally distributed in both consanguineous
and nonconsanguineous pedigrees (Table 1). Of the total fam-
ilies recruited, 51.5% belonged to the nonconsanguineous
group. Sporadic cases accounted for 80%, and bilateral 88%.
Males accounted for 57% of the affected individuals.
Mutations at codon 390, where arginine is changed to either
histidine or serine, have been reported.10,12 This is the first
report of arginine changing to cysteine at the same codon.
Hin6I-based PCR-RFLP can be therefore used to detect any of
these mutations at this codon. Although mutations at codons
368 and 390 have been reported earlier, our report of this
combination of mutations is novel, as is the sequence variation
in codon 390. This two-generation affected family is also inter-
esting in that whereas the affected father (II.1) had a homozy-
gous mutation (R390C), the mother (II.2) was a carrier of one
of the alleles (R368H; data not shown), and the proband (af-
fected child 111.2) had a compound heterozygous mutation
(R390C and R368H). Consistent with the autosomal mode of
inheritance, the affected individuals (II.1 and III.2) in this
pedigree had two mutant alleles from their respective parents;
the mutations were completely penetrant.
Consanguineous marriages and marriages within a distinc-
tive caste or community increase the predisposition and inci-
dence of recessively inherited and multifactorial diseases in the
population. It is important to know the carrier status of unaf-
fected members in the families with a positive history to
identify the at-risk individuals in such families. Earlier studies
have reported that 30% to 35% of blind children in India show
a history of hereditary disorder.22 In the higher socioeconomic
levels of developed countries, 22% to 55% of children with
genetic disease show an autosomal recessive mode of inheri-
tance.23 Hence, development of techniques such as PCR-RFLP,
the amplification refractory mutation system (ARMS)-PCR, al-
lele-specific oligonucleotide (ASO) blot analysis, and other
methods are important for segregation analysis in families with
a positive history and for possible prenatal diagnosis and ge-
netic counseling. Moreover, because this disease carries high
and life-long morbidity, development of strategies that are
noninvasive, rapid, and cost-effective are very useful in screen-
ing populations with a high incidence of this disease. This
could in turn help in identifying individuals at risk and also
assist in preventing unwanted visual loss in the afflicted fami-
lies. An earlier study on thalassemia major in a Sardinian pop-
ulation showed that genetic screening and counseling helped
to reduce the incidence from 1 in 250 live births to 1 in 4000.24
Similarly, the molecular diagnostic methods used in the
current study could be used as an added clinical tool in de-
creasing the incidence of the devastating binding disorder PCG
in the afflicted families.
Moreover, our clinical experience in PCG has shown that
early diagnosis, along with prompt medical and surgical inter-
ventions, result in better prognosis.25 We thus see the use of
the PCR-RFLP molecular diagnosis described in this study as a
tool to identify the disease early and to initiate appropriate and
prompt treatments, especially in patients with late manifesta-
tion and positive family history. Based on this study, we sug-
gest that PCG mutation screening in India should be performed
based on the prevalence of the mutation.
Our study shows that 31% of the patients studied had one of
the six mutations that we sought in the screening. Whereas
only direct screening or methods such as denaturing HPLC can
identify all mutations in CYP1B1, R368H appears to be the
predominant mutant allele causing PCG in the population stud-
ied herein. Given this lead, we believe that screening for this
mutation should be given priority, and subsequently the other
reported mutations should be screened for in the order of
prevalence. Thus, the data derived from this study highlight the
use of a rapid screening system for mutations that could assist
the medical community in the management of this devastating
condition
TABLE 1. Distribution of Six Mutations in Consanguineous and
Nonconsanguneous, Pedı´grees
Pedigree ID Mutation
Consanguineous/
Nonconsanguineous
0001 (2) P193L (h) Consanguineous
E229K (h)
0002 R368H (H) Consanguineous
0004 (2) 376Ins A H) Consanguineous
0005 (2) R368H (h) Nonconsanguineous
R390C (h)
0006 (2) R368H (H) Consanguineous
0011 G61E (H) Consanguineous
0012 (2) R390C (H) Consanguineous
0017 R368H (H) Nonconsanguineous
0018 R390C (H) Consanguineous
0022 R368H (H) Consanguineous
0024 E229K (h) Consanguineous
0025 R368H (h) Nonconsanguineous
0035 (2) R368H (H) Consanguineous
0037 E229K (h) Consanguineous
0039 R368H (h) Nonconsanguineous
0040 R368H (H) Consanguineous
0051 R368H (H) Nonconsanguineous
0057 E229K (h) Consanguineous
0058 G61E (H) Consanguineous
0067 R368H (H) Consanguineous
0069 P193L (h) Nonconsanguineous
0071 (2) R368H (H) Nonconsanguineous
0075 R368H (h) Nonconsanguineous
0076 R368H (H) Consanguineous
0079 R368H (H) Nonconsanguineous
0092 R390C (H) Nonconsanguineous
0093 (2) G61E (H) Consanguineous
0095 R368H (h) Nonconsanguineous
0100 R368H (h) Consanguineous
0116 E229K (h) Consanguineous
0125 E229K (h) Nonconsanguineous
0130 R368H (H) Nonconsanguineous
0136 R368H (H) Nonconsanguineous
0137 R368H (H) Nonconsanguineous
0143 R390C (H) Nonconsanguineous
0144 R368H (H) Nonconsanguineous
0150 R368H (H) Nonconsanguineous
h, Heterozygous mutation; H, homozygous mutation; (2) two
patients in the same pedigree.
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